Cefamandol (Cefamandolum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation
  • Cefamabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Cefat®
    powdersolution for injections 
    SYNTHESIS, OJSC     Russia
    • АТХ:

    J.01.D.C.03   Cefamandol

    Pharmacodynamics:

    Cephalosporin antibiotic II generation for parenteral use.

    Has a bactericidal effect due to the inhibition of the synthesis of bacterial cell membranes. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. Suppresses the activity of the endogenous inhibitor, inhibits peptidoglycan transpeptidase, which leads to the activation of murein hydrolase, which cleaves peptidoglycan. Effective against bacteria in the period of division, at this time in their membranes is the synthesis of peptidoglycan.

    It has bactericidal action against gram-negative and gram-positive microorganisms: Escherichia coli, Providencia rettgeri, Klebsiella spp., Haemophilus influenzae, Proteus mirabilis, Enterobacter spp., Morganella morganii, some strains Proteus vulgaris, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Gram-positive and gram-negative anaerobes: Peptococcus, Peptostreptococcus spp., Clostridium spp., Bacteroides, Fusobacterium spp.

    Pharmacokinetics:

    After intramuscular injection, the maximum concentration in the blood plasma is reached after 30-120 minutes, after intravenous - in 10 minutes.

    Not exposed to metabolism. Penetrates through the placental barrier, is found in breast milk.

    The half-life is 32 minutes after intravenous administration, 60 minutes after intramuscular injection. Elimination of the kidneys unchanged.

    Indications:

    It is used to treat infections caused by pathogens that are sensitive to cefamandol: abdominal, gynecological, urinary tract infections, respiratory tract, bones and joints, skin and soft tissues, meningitis, sepsis, endocarditis; burn infections. Used to prevent postoperative infectious complications.

    ICD-10

    I.A30-A49.A39   Meningococcal infection

    I.A30-A49.A40   Streptococcal septicemia

    I.A30-A49.A41   Other septicemia

    VI.G00-G09.G00   Bacterial meningitis, not elsewhere classified

    IX.I30-I52.I33   Acute and subacute endocarditis

    X.J00-J06.J00   Acute nasopharyngitis (runny nose)

    X.J30-J39.J31.1   Chronic nasopharyngitis

    X.J30-J39.J31   Chronic rhinitis, nasopharyngitis and pharyngitis

    X.J00-J06.J01   Acute Sinusitis

    X.J30-J39.J32.9   Chronic sinusitis, unspecified

    X.J30-J39.J31.2   Chronic pharyngitis

    X.J00-J06.J02.0   Streptococcal pharyngitis

    X.J00-J06.J02   Acute pharyngitis

    X.J00-J06.J03   Acute tonsillitis

    X.J30-J39.J35.0   Chronic tonsillitis

    X.J00-J06.J04   Acute laryngitis and tracheitis

    X.J10-J18.J15   Bacterial pneumonia, not elsewhere classified

    X.J20-J22.J20   Acute bronchitis

    X.J40-J47.J42   Chronic bronchitis, unspecified

    X.J40-J47.J40   Bronchitis, not specified as acute or chronic

    XI.K65-K67.K65.0   Acute peritonitis

    XI.K80-K87.K81.1   Chronic cholecystitis

    XI.K80-K87.K81.0   Acute cholecystitis

    XI.K80-K87.K83.0   Cholangitis

    XII.L00-L08.L01   Impetigo

    XII.L00-L08.L02   Abscess of skin, boil and carbuncle

    XII.L00-L08.L03   Phlegmon

    XII.L00-L08.L08.0   Pyoderma

    XIII.M00-M03.M00   Pyogenic arthritis

    XIII.M86-M90.M86   Osteomyelitis

    XIV.N10-N16.N12   Tubulointerstitial nephritis, not specified as acute or chronic

    XIV.N10-N16.N11.9   Chronic tubulointerstitial nephritis, unspecified

    XIV.N10-N16.N10   Acute tubulointerstitial nephritis

    XIV.N30-N39.N30   Cystitis

    XIV.N30-N39.N34   Urethritis and urethral syndrome

    XIV.N40-N51.N41   Inflammatory diseases of the prostate

    XIV.N70-N77.N70   Salpingitis and oophoritis

    XIV.N70-N77.N71.0   Acute inflammatory disease of the uterus

    XIV.N70-N77.N72   Inflammatory disease of the cervix

    XIV.N70-N77.N73.0   Acute parametritis and pelvic cellulite

    XIX.T79.T79.3   Post-traumatic wound infection, not elsewhere classified

    XXI.Z20-Z29.Z29.2   Another type of preventive chemotherapy

    Contraindications:

    Individual intolerance to β-lactam antibiotics: penicillins and cephalosporins.

    Carefully:

    Imbalance of electrolytes or fluids, severe liver damage, neonatal period.

    Pregnancy and lactation:

    Recommendations for FDA - Category B.It is used in pregnancy and lactation.

    Dosing and Administration:

    Use in children

    Intramuscularly and intravenously, 50-100 mg / kg per day, every 4-8 hours.

    Adults

    Intravenous and intramuscularly 0.5-1.0 g every 4-8 hours.

    To prevent postoperative purulent complications - 30-60 minutes before surgery 1-2 g, followed by the same dose for 1-2 days.

    The highest daily dose: 12 g.

    The highest single dose: 2 g.

    Side effects:

    Central and peripheral nervous system: rarely - convulsions.

    Hemopoietic system: thrombocytopenia, eosinophilia, leukopenia, an increase in prothrombin index and coagulation time.

    Digestive system: nausea, vomiting, diarrhea, increased activity of hepatic enzymes, hepatic or cholestatic jaundice, intestinal dysbacteriosis.

    Dermatological reactions: local reactions - compaction at the injection site, candidiasis dermatitis, vulvovaginitis.

    urinary system: rarely - the development of hypokalemia.

    Allergic reactions.

    Overdose:

    Nausea, vomiting, diarrhea, neuromuscular excitability, convulsive attacks.

    Treatment is symptomatic, hemodialysis.

    Interaction:

    Simultaneous use with probenecid slows the renal excretion of cefamandole.

    "Loop diuretics" block the tubular secretion of cefamandole.

    Special instructions:

    Simultaneous use with ethanol can cause a disulfiram-like reaction.

    Instructions
    Up